Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia
A Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia
Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.
Listed as NCT06004856, this PHASE3 trial focuses on Chronic Primary Immune Thrombocytopenia (ITP) and remains actively recruiting participants. Sponsored by Beijing InnoCare Pharma Tech Co., Ltd., it has been updated 6 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Recruiting PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE3
-
Feb 2024 — Jun 2024 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
▶ Show 1 earlier version
-
Sep 2023 — Feb 2024 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Beijing InnoCare Pharma Tech Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Beijing, China , Bengbu, China , Changsha, China , Chengdu, China , Chenzhou, China , Chongqing, China , Dezhou, China , Fuzhou, China , Guangzhou, China , Hangzhou, China and 25 more locations